We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (Probio'Stick / Cerebiome)
The 'psychobiotic' combination behind Probio'Stick and Cerebiome — always a fixed two-strain pair, never L. helveticus alone. One 110-person trial in diagnosed depression is genuinely positive at p=0.042; an independent 135-person trial in healthy adults was null on every pre-specified outcome; and the widely cited founding trials were either GI-only or reported without sample sizes.
What the evidence says
Most L. helveticus R0052 + B. longum R0175 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2008–2025 with a typical study size of 78 participants.
Based on 8 studies · 5 RCTs · 359 total participants
Confidence
Moderate confidenceBy outcome
One genuinely positive trial in diagnosed depression, undercut by 26% attrition and no independent replication — the most-cited follow-up is a post hoc analysis of the same cohort, and the one independent trial in healthy adults was null on every pre-specified outcome. No meta-analysis exists.
No trials currently enrolling · 2 completed on ClinicalTrials.gov
1 of the completed trials have posted results
Registered trials show research momentum for L. helveticus R0052 + B. longum R0175, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Under EU law (Reg. 1924/2006), EFSA reviews whether a specific health claim for L. helveticus R0052 + B. longum R0175 meets the evidence standard. These are independent regulatory decisions on claims — not studies, and never counted toward the evidence score above.
Not authorised by EFSA
“Lactobacillus helveticus I- 1722 - probiotic -helps body's natural defences; '-helps to strenghten the natural defenses; '-helps to stimulate the immune system”
“Not authorised” means the specific claim wording did not meet the EU’s evidence standard — often a matter of dossier or phrasing, not proof of no effect. EFSA judges marketing claims and is kept separate from our study-based evidence score.
Source: EU Register of nutrition and health claims (European Commission / EFSA) · register snapshot Feb 2013
Our research database did not respond in time, so the studies and count above cover only our curated set. This refreshes automatically.
This entry covers a fixed two-strain combination — Lactobacillus helveticus R0052 together with Bifidobacterium longum R0175 — sold as Probio'Stick and Cerebiome. There is no human evidence for L. helveticus alone as a mood agent, and none for B. longum R0175 alone in this role either.
Every human trial below used the pair. That matters because the two strains are not interchangeable with the many other L. helveticus or B. longum products on the market, and because the only study that has ever compared the combination against each strain individually was conducted in mice.
A naming trap compounds this: the founding 2008 trial called the first organism Lactobacillus acidophilus Rosell-52, and it was later reclassified as Lactobacillus helveticus — so Rosell-52, R0052 and 'L. acidophilus Rosell-52' all name the same strain.
Unlike the Lactobacillus casei Shirota strain, L. helveticus was NOT renamed by the 2020 genus split; it remains in the emended genus Lactobacillus. The evidence is thin and pulls in opposite directions.
The strongest result is an 8-week Iranian trial in patients with diagnosed major depressive disorder, where Beck Depression Inventory scores fell from 17.39 to 9.1 on the combination versus 18.18 to 15.55 on placebo (p=0.042) — a real effect in a real patient population, but from 110 randomised of whom only 81 completed, roughly 26% attrition, and with the kynurenine/tryptophan biomarker reaching significance only after adjusting for serum isoleucine.
A widely cited follow-up showing large BDNF increases is explicitly a post hoc analysis of that same cohort, not an independent replication.
Pointing the other way: a 135-person trial in healthy adults with no author financial ties (though the manufacturer supplied the product and placebo) found no significant effect of the combination on any pre-specified outcome — wellbeing, quality of life, emotional regulation, anxiety, mindfulness or interoceptive awareness — with only a post hoc lifestyle-interaction term coming out positive.
The founding Probio'Stick trial found benefit for abdominal pain and nausea only, with psychological symptoms and sleep explicitly unchanged. And a 2025 trial in female dancers found no improvement in gastrointestinal symptoms at all.
The plausible read is a possible effect in people who are actually depressed, and no demonstrated effect in people who are not.
Serum brain-derived neurotrophic factor rose significantly on the combination versus both prebiotic (P<0.001) and placebo (P=0.021), and inversely correlated with depression severity (r=-0.79). This is the most-cited mechanistic finding for the pair — but it comes from a post hoc analysis of the same 110-person cohort as the efficacy result, in 28 probiotic-group participants, so it is hypothesis-generating.
The kynurenine/tryptophan ratio decreased significantly versus placebo — but only after adjusting for serum isoleucine (p=0.048). The unadjusted between-group comparison was not significant, which is worth knowing before treating this as an established mechanism.
In stressed mice, the combination up-regulated glucocorticoid receptor mRNA across hypothalamus, hippocampus and prefrontal cortex and normalised the stress response, while either strain alone was less effective. This is the only evidence that the pair beats its components — and it is not human evidence.
How L. helveticus R0052 + B. longum R0175 works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
This is the population where the evidence is strongest and also where self-treatment carries the most risk. The one positive trial was 8 weeks in patients with MDD — it is not a substitute for treatment, and the effect has not been independently replicated.
Tested directly in 135 healthy adults and null on every pre-specified outcome. This is the most common consumer use case and the one with the clearest negative result.
No data — untested rather than shown safe. Discuss with a clinician.
Standard live-probiotic caution applies; no strain-specific data exists either way.
Antibacterial antibiotics reduce the viable dose of a live bacterial product. No trial of this R0052 + R0175 combination tested concurrent antibiotics, so the size of the effect is unknown. Separating doses by about 2 hours is a reasonable precaution.
Not an interaction with the drug itself — the concern is adding a live organism to a host who cannot contain it. This is documented rather than theoretical: whole-genome work traced Lactobacillus blood isolates in ICU patients directly to the probiotic capsules they were given. Avoid unless a clinician directs otherwise; the same caution applies to critical illness and an indwelling central venous catheter.
Tip: An open-label study in 10 treatment-naive MDD patients reported no side effects or adverse effects over 8 weeks, and the dancer trial reported no adverse events
L. helveticus R0052 + B. longum R0175 has an evidence score of 3/10 — emerging evidence based on 9 indexed studies. The 'psychobiotic' combination behind Probio'Stick and Cerebiome — always a fixed two-strain pair, never L. helveticus alone. One 110-person trial in diagnosed depression is genuinely positive at p=0.042; an independent 135-person trial in healthy adults was null on every pre-specified outcome; and the widely cited founding trials were either GI-only or reported without sample sizes. Representative study: PMID 37049546.
The commonly studied dose of L. helveticus R0052 + B. longum R0175 is 3 x 10^9 CFU daily of the fixed combination (L. helveticus R0052 plus B. longum R0175) — the dose used in the founding trial, the dancer trial and the open-label MDD study. No dose-comparison study exists.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for L. helveticus R0052 + B. longum R0175 — consistent daily use matters more than the time of day. No trial compared time of day or fed versus fasted dosing.
L. helveticus R0052 + B. longum R0175 is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include mild digestive upset. Use caution if any of these apply to you: Immunocompromise or immunosuppression (class-level precaution for live probiotics); Critical illness or indwelling central venous catheter.
Probiotics
Likely helpsLive microorganisms where strain selection determines outcome — Lactobacillus and Bifidobacterium strains best studied for gut, immune, and mood.
Saccharomyces Boulardii
Likely helpsAntibiotic-resistant probiotic yeast that supports digestive regularity and gut flora during travel and antibiotic use.
B. lactis (BB-12 / HN019)
Mostly mechanism / observationalThe most-replicated probiotic effect on gut transit — it measurably speeds things up and adds roughly one bowel movement a week in people who are already low. But it is not a constipation cure: the two largest, best-designed trials both missed their primary endpoints, and the honest effect is hours off transit time, not a fix.
L. rhamnosus GG
Mostly mechanism / observationalOne of the two most-studied probiotic strains, and a case study in why strain-level evidence matters. It has one genuinely strong, guideline-endorsed use — preventing antibiotic-associated diarrhea in children — while its two most-marketed uses, treating stomach bugs and preventing eczema, were both overturned by the largest and best-run trials.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Body Health
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 8 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research